Indications of dacomitinib/dacomitinib and its latest selling price

Dacomitinib/Dacomitinib (Dacomitinib) is a second-generation EGFR tyrosine kinase inhibitor developed by Pfizer Pharmaceuticals. Its primary indication is for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancerwith sensitizing mutations in the epidermal growth factor receptor (EGFR). Especially in patients with EGFR mutations who have not received systemic treatment, dacomitinib is often used as one of the first-line treatment options. It blocks signal transduction by irreversibly binding to members of the EGFR receptor family, thereby inhibiting the growth and spread of cancer cells and significantly extending the progression-free survival of patients.

In clinical application, dacomitinib has attracted much attention due to its long-term efficacy advantages. Compared with the first-generation EGFR inhibitors, it not only has a longer duration of action, but also remains active in the environment of some drug-resistant mutations. Therefore, international guidelines generally recommend it as an important treatment option for EGFR mutant lung cancer. Although the drug still has certain side effects, including rash, diarrhea, oral inflammation, loss of appetite, etc., most of them can be alleviated through dose adjustment or symptomatic treatment, so the overall tolerance is good.

In terms of selling price, the original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The common specification of 15mg*30 tablets may cost more than 1,000 yuan per box; the European version of dacomitinib original drug sold overseas, with the specification of 45mg*30 tablets, may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are also cheaper generic drugs of Dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold at home and abroad, such as Laos Lucius Pharmaceutical Factory and Laos Element Pharmaceutical Factory. The price of their specifications 45mg*30 tablets per box may be around 800 RMB (the price may fluctuate due to the exchange rate).

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro